We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Basic Lipid Panel Faulted in Heart Disease Risk

By LabMedica International staff writers
Posted on 23 Apr 2013
The basic lipid panel could be leaving millions at risk due to errors in estimation of low-density lipoprotein (LDL) cholesterol levels, even though it is relied upon for more than 85% of adult cholesterol testing each year.

The accuracy of the Friedewald equation in calculated LDL cholesterol measurement using the traditional basic lipid panel or standard cholesterol test, has been compared to directly measured LDL-C in the comprehensive commercial VAP Lipid Panel.

Scientists at Johns Hopkins Ciccarone Center (Baltimore, MD, USA) working with colleagues from different institutes, examined consecutive lipid profiles from a clinical sample of 1,340,614 US adults who were 18 years of age or older and whose blood sample underwent vertical spin density gradient ultracentrifugation of cholesterol from 2009 to 2011. More...
The mean age of the patients was 59 years and 52% were women.

Lipid measurements included inverted rate zonal, single vertical spin, density gradient ultracentrifugation by the Vertical Auto Profile (VAP) technique (Atherotech Diagnostics Lab; Birmingham, AL, USA). This technique directly measures LDL-C, very low density lipoprotein cholesterol (VLDL-C), intermediate-density lipoproteins cholesterol (IDL-C), lipoprotein (a) cholesterol (Lp(a)-C), and high density lipoprotein cholesterol (HDL-C). VAP accuracy was examined yearly from 2007 to 2012.

The results of the study showed that the basic lipid panel underestimated risk in 23% to 59% of patients with Friedewald estimated LDL cholesterol levels below 70 mg/dL and triglycerides above 150 mg/dL, which could result in under treatment of high-risk patients.

The authors concluded that the Friedewald equation tends to underestimate LDL-C mainly when accuracy is most crucial, especially if triglycerides are equal to or greater than 150 mg/dL. Friedewald estimation commonly classifies LDL-C as less than 70 mg/dL despite directly measured levels equal to or greater than 70 mg/dL, and therefore additional evaluation is warranted in high-risk patients.

Steven R. Jones, MD, the senior investigator said, "It's the first time we've compared LDL cholesterol measurements using the Friedewald calculation to the density gradient ultracentrifugation method, which directly measures LDL cholesterol. What's important in this study is that Friedewald and direct LDL cholesterol are most different, with Friedewald LDL generally lower than direct LDL, when accuracy is most crucial in patients with LDL cholesterol levels in the high-risk treatment target range and elevated triglycerides." The study was published on March 20, 2013, in the Journal of the American College of Cardiology.

Related Links:
Johns Hopkins Ciccarone Center
Atherotech Diagnostics




New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Serological Pipet Controller
PIPETBOY GENIUS
New
Capillary Blood Collection Tube
IMPROMINI M3
New
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.